Dengue epidemic in Northern Peru (2024): analysis of 2,449 cases.

Med Clin (Barc)Jun 29, 2026 (epub)
Case ReportInfectious DiseasesInternal Medicine (General)

Luis Ángel Rodríguez-Chávez, Maribel Luz Esteban-Dionicio

✦ AI-curated · Sources linked

Case in brief

During the 2024 dengue epidemic in northern Peru, a retrospective analysis of 2,449 confirmed cases revealed that 54.4% had dengue without warning signs, 45.0% had dengue with warning signs, and 0.7% had severe dengue. Common symptoms included fever, headache, and lumbar pain, while patients with more severe cases exhibited chest pain and encephalopathy. The study highlighted a notable prevalence of cardiovascular and renal comorbidities in these patients.

Diagnostic / clinical pearl

Clinicians should be aware that dengue cases with warning signs are prevalent and that comorbidities can significantly impact clinical severity.

Why it matters

Understanding the association between comorbidities and dengue severity can aid in risk stratification and management of affected patients.

Source

PubMed · PMID 42372495

Published in Med Clin (Barc). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.